Demo brain. Umbrella Corporation is a fictional client invented to demonstrate Loomery’s project-brain tooling. Everything below is simulated content, written in the same cited style a real engagement’s docs would use — see onboarding-status for the full disclosure.

Engagement

One-paragraph purpose: what Umbrella Corporation is, why Loomery is engaged, and the current phase — kept current here so any AI session gets it in one read.

Summary

Umbrella Corporation is a multinational pharmaceutical and consumer health company headquartered in Raccoon City, with an Applied Biosciences division running R&D labs across six sites worldwide. Loomery is engaged to replace UMBRA, Applied Biosciences’ 20-year-old on-prem lab-operations system, with Hive OS — a modern, compliance-grade platform covering facility access, sample inventory, and audit reporting. The SOW was signed 2026-05-20; Discovery ran through July; delivery of Phase 1 (Facility Access & Sample Inventory) started 2026-08-06 and is now in Sprint 2. (source: Granola note “SOW Sign-Off Call”, 2026-05-20; Granola note “Phase 1 Scope Review”, 2026-07-30)

Timeline

• 2026-05-20 — SOW signed.
• 2026-06-15 — Kickoff.
• 2026-06-15 – 2026-07-30 — Discovery: facility access workflows (2026-07-02) and sample inventory / compliance reporting (2026-07-16), wrapping with a Phase 1 scope review (2026-07-30).
• 2026-08-06 — Delivery kickoff, Sprint 1 planning.
• 2026-08-13 — Sprint 1 review, Sprint 2 planning.
• Target: 2026-11-13 — Phase 1 (Facility Access & Sample Inventory) live at the Raccoon City pilot site, ahead of Umbrella’s 2027 FDA audit cycle. (source: Google Drive, “Umbrella × Loomery — SOW v1.2”; Granola notes, kickoff and discovery sessions, 2026-06-15 to 2026-07-30)

Goals

Umbrella’s “One Hive” initiative aims to consolidate six regional, independently-run lab-ops systems onto a single platform before the 2027 FDA audit cycle — driven by Priya Anand (Head of Compliance & Quality), who flagged UMBRA’s lack of a unified audit trail as the single biggest audit risk. Phase 1 success is measured on three things: facility access requests resolved without a manual override, sample chain-of-custody fully reconstructable from the system alone (zero paper backstops), and a successful pilot cutover at the Raccoon City site with no UMBRA rollback. (source: Granola note “Phase 1 Scope Review”, 2026-07-30 — Priya: “if an auditor can’t reconstruct custody from the system alone, we’ve failed, full stop”)

Group interest

Hive OS is being watched above the Applied Biosciences division: at the quarterly Group Steering Committee (2026-08-14), Group CIO Wendy Ashford flagged interest in using it as the template for modernising Umbrella Pharmaceuticals’ and Umbrella Consumer Health’s own legacy plant-ops systems, contingent on a clean Raccoon City pilot cutover — meaning Phase 1’s outcome now has weight beyond this one division. Group CFO Robert Kaine confirmed Phase 1 budget is on track at the same meeting. (source: Granola note “Group Steering Committee — Q3 Review”, 2026-08-14)

See also stakeholders for who owns each of these goals, and product-context for what Hive OS actually does.